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Background: To evaluate the relationship between the low-density lipoprotein cholesterol (LDL-C)/high-density
lipoprotein cholesterol (HDL-C) ratio and HDL subclass distribution and to further examine and discuss the
potential impact of LDL-C and HDL-C together with TG on HDL subclass metabolism.
Results: Small-sized preb1-HDL, HDL3b and HDL3a increased significantly while large-sized HDL2a and HDL2b
decreased significantly as the LDL-C/HDL-C ratio increased. The subjects in low HDL-C level (< 1.03 mmol/L) who
had an elevation of the LDL-C/HDL-C ratio and a reduction of HDL2b/preb1-HDL regardless of an undesirable or
high LDL-C level. At desirable LDL-C levels (< 3.34 mmol/L), the HDL2b/preb1-HDL ratio was 5.4 for the subjects
with a high HDL-C concentration (≥ 1.55 mmol/L); however, at high LDL-C levels (≥ 3.36 mmol/L), the ratio of
LDL-C/HDL-C was 2.8 in subjects, and an extremely low HDL2b/preb1-HDL value although with high HDL-C
concentration.
Conclusion: With increase of the LDL-C/HDL-C ratio, there was a general shift toward smaller-sized HDL particles,
which implied that the maturation process of HDL was blocked. High HDL-C concentrations can regulate the HDL
subclass distribution at desirable and borderline LDL-C levels but cannot counteract the influence of high LDL-C
levels on HDL subclass distribution.
Introduction
Lipid abnormalities have long been suspected to contri-
bute to atherosclerosis (As); there is overwhelming evi-
dence [1,2] that an elevated low-density lipoprotein
cholesterol (LDL-C) concentration in plasma is athero-
genic, whereas a higher high-density lipoprotein choles-
terol (HDL-C) level is cardioprotective [2-4]. A series of
studies suggested that the use of the ratio of LDL-C to
HDL-C is superior to the use of HDL-C or LDL-C
alone [5] and that the ratio of LDL-C/HDL-C may
provide better risk assessment by concurrently account-
ing for both atherogenic and protective lipid fractions.
The cardioprotective effect of HDL has been largely
attributed to its role in reverse cholesterol transport
(RCT), wherein excessive cholesterol is conveyed from
peripheral tissues to the liver and steroidogenic organs.
HDL encompasses a heterogeneous class of lipoproteins.
Differences in the quantitative and qualitative content of
lipids, apolipoproteins (apos), and enzymes result in the
presence of various HDL subclasses, which are charac-
terized by differences in size, shape, charge and antigen-
city [6]. Using two-dimensional gel electrophoresis
coupled with immunoblotting, HDL can be divided into
large, cholesterol-rich (HDL2a and HDL2b), small, lipid-
poor (HDL3c,H D L 3b,H D L 3a,a n dp r e b1-HDL) and
preb2-HDL. It has been postulated that RCT indeed is
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efficiently from the cell membrane, is then transformed
by the action of lecithin-cholesterol acyltransferase
(LCAT), and is finally remodeled further by the activities
of other plasma factors, such as hepatic lipase (HL),
cholesterol ester transfer protein (CETP), and lipopro-
tein lipase (LPL), such that the nascent lipid-poor preb1-
HDL is converted into mature, cholesterol-rich, spheri-
cal HDL2, following the pathway of preb1-HDL ®
preb2-HDL ® preb3-HDL ® HDL3 ® HDL2 [7-9]. The
distribution of HDL subclasses can effectively reflect the
efficiency of RCT and may directly impact the athero-
genic progress.
Some investigators have reported the impaired conver-
sion of preb1-HDL to a-migrating HDL, thereby ham-
pering RCT and likely contributing significantly to the
high frequency of cardiovascular disease (CVD) occur-
rence in hemodialysis patients [10]; and other research
has shown that concentrations of HDL2 are directly
related to the efficiency in the clearance of triglyceride-
rich fractions and exhibit the strongest negative correla-
tion with both the advent and the extent of coronary
atherosclerosis [11-13].
We have previously investigated the impact of plasma
lipids together with their ratios on HDL subclass distri-
bution and found that the particle size of HDL became
smaller with the rise in plasma triglyceride (TG), TC,
LDL-C levels, and TG/HDL-C along with total choles-
terol (TC)/HDL-C ratios or with the fall of HDL-C levels
[14-17]. Although the ratio of LDL-C/HDL-C shows pro-
mises as an attractive surrogate index of the atherogeni-
city of the plasma lipid profile, few data with regard to
the association between the LDL-C/HDL-C ratio and the
pattern of HDL subclass distribution are available. In this
work, we evaluated the correlation between lipid vari-
ables, mainly the LDL-C/HDL-C ratio and the HDL sub-
class distribution profile in the Chinese population. HDL
characterized by particle size could provide an important
key to interpreting the effects of lipid parameters on
HDL-related coronary heart disease (CHD) risk.
Results
Concentrations of plasma lipids, lipoproteins,
apolipoproteins and the contents of HDL subclasses
classified based on values of LDL-C to HDL-C
Characteristics of subgroups classified based on the
LDL-C/HDL-C ratio were presented in Table 1. The
concentrations of TG, TC, LDL-C and apoB-100 along
with the ratios of TG/HDL-C, TC/HDL-C, and LDL-C/
HDL-C increased successively; however, those of HDL-
C and apoA-I decreased progressively with the elevation
of the LDL-C/HDL-C ratio.
Table 1 Concentrations of plasma lipids, lipoproteins, and contents of HDL subclasses according to category of LDL-C/
HDL-C ratio
LDL-C/HDL-C≤2.3 2.3<LDL-C/HDL-C≤3.9 3.9<LDL-C/HDL-C≤4.6 LDL-C/HDL-C>4.6
N 166 261 48 35
Age(y) 56.0 ± 9.4 56.6 ± 9.6 57.4 ± 9.1 58.1 ± 8.6
BMI(kg/m
2) 22.6 ± 2.8 23.9 ± 3.0 24.6 ± 2.9
a* 25.0 ± 3.6
a*
TG(mmol/L) 1.7 ± 0.2 2.1 ± 0.3
a† 2.4 ± 0.5
a§b† 2.8 ± 0.4
a§b§c†
TC(mmol/L) 5.0 ± 0.3 5.6 ± 0.5
a† 6.4 ± 0.8
a§b† 6.9 ± 0.7
a§b§c†
LDL-C(mmol/L) 2.5 ± 0.4 3.5 ± 0.5
a† 4.3 ± 0.5
a§b† 4.7 ± 0.7
a§b§c*
HDL-C(mmol/L) 1.5 ± 0.2 1.2 ± 0.3
a§ 0.9 ± 0.2
a§b§ 0.7 ± 0.2
a§b§c†
TG/HDL-C 1.6 ± 0.3 2.2 ± 0.4
a† 2.8 ± 0.4
a§b† 3.6 ± 0.5
a§b§c†
TC/HDL-C 3.5 ± 0.7 5.0 ± 1.0
a§ 6.7 ± 0.8
a§b§ 8.2 ± 1.2
a§b§c§
LDL-C/HDL-C 1.7 ± 0.5 3.0 ± 0.4
a§ 4.4 ± 0.4
a§b§ 5.6 ± 1.0
a§bc§§
ApoA-I (mg/L) 1364.1 ± 114.2 1244.7 ± 109.2
a† 1221.9 ± 105.8
a† 1120.2 ± 116.9
a§b†c†
ApoB100(mg/L) 803.6 ± 82.7 921.2 ± 89.0
a† 1087.9 ± 90.3
a§b† 1198.4 ± 93.2
a§b§c†
Preb1-HDL(mg/L) 81.2 ± 20.2 103.1 ± 25.7
a* 121.9 ± 27.3
a†b* 144.0 ± 35.9
a§b†c*
Preb2-HDL(mg/L) 59.6 ± 15.3 62.2 ± 19.3 67.1 ± 17.5 68.8 ± 22.0
HDL3c(mg/L) 72.2 ± 21.6 74.9 ± 25.1 78.9 ± 21.6 83.9 ± 20.1
HDL3b(mg/L) 140.8 ± 34.5 149.8 ± 37.8 173.4 ± 35.3
a†b* 217.2 ± 33.1
a†b§c†
HDL3a(mg/L) 274.9 ± 47.5 298.3 ± 58.3
a* 314.7 ± 90.7
a†b* 368.0 ± 92.1
a§b§c†
HDL2a(mg/L) 314.3 ± 81.7 291.0 ± 50.6
a* 250.8 ± 35.1
a§b† 213.2 ± 24.8
a§b§c†
HDL2b(mg/L) 387.3 ± 95.7 313.4 ± 79.7
a§ 261.7 ± 39.8
a§b§ 205.8 ± 29.2
a§b§c§
Values are expressed as Mean ± S.D
*P <0 . 0 5 ,
†P <0 . 0 1 ,
§P < 0.001
aSignificantly different from LDL-C/HDL-C≤2.3 group
bSignificantly different from 2.3<LDL-C/HDL-C≤3.9 group
cSignificantly different from 3.9<LDL-C/HDL-C≤4.6 group
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ized by elevated contents of small-sized preb1-HDL,
HDL3b and HDL3a, whereas there was a reduction in the
contents of large-sized HDL2a and HDL2b with the ele-
vation of the LDL-C/HDL-C ratio.
Characteristics of plasma apoA-I contents of HDL
subclasses among subjects categorized by TG levels (2.26
mmol/L) and LDL-C/HDL-C ratio (3.5)
As Table 2 shows, the contents of preb1-HDL and
HDL3a were significantly lower, while the concentrations
of HDL2a and HDL2b were significantly higher for sub-
jects in the LDL-C/HDL-C < 3.5 group, compared with
their counterparts in the LDL-C/HDL-C ≥3.5 group.
Both in the LDL-C/HDL-C < 3.5 and LDL-C/HDL-C
≥3.5 groups, small-sized preb1-HDL and HDL3a
increased; however, large-sized HDL2a and HDL2b
decreased more in the TG ≥2.26 mmol/L subgroup than
in the corresponding TG < 2.26 mmol/L subgroup.
In addition, in the TG < 2.26 mmol/L and TG ≥ 2.26
mmol/L groups, the contents of preb1-HDL (except TG
≥ 2.26 mmol/L group) and HDL3a increased signifi-
cantly; in contrast, those of HDL2a and HDL2b decreased
significantly in the LDL-C/HDL-C ≥ 3.5 group com-
pared with in the LDL-C/HDL-C < 3.5 group.
ApoA-I contents of plasma HDL subclasses according to
plasma LDL-C and HDL-C concentrations among subjects
As shown in Figure 1, compared to the low HDL-C (<
1.03 mmol/L) subgroup, preb1-HDL decreased signifi-
cantly but HDL2b increased significantly in the corre-
sponding middle HDL-C (1.03-1.52 mmol/L) and high
HDL-C (≥ 1.55 mmol/L) subgroups, both in desirable
LDL-C (< 3.34 mmol/L) and borderline LDL-C (3.36-
4.11 mmol/L) groups. On the contrary, in the high
LDL-C (≥ 4.14 mmol/L) group, preb1-HDL (high HDL-
C subgroup) and HDL2b contents were markedly higher
in the middle and high HDL-C subgroups than in the
corresponding low HDL-C subgroup.
Moreover, in the borderline and high LDL-C groups, a
reduction of preb1-HDL and HDL2b contents was evi-
dent in the low HDL-C subgroup; in contrast, the con-
tents of preb1-HDL were obviously higher in the middle
(high LDL-C group) and high HDL-C subgroups, while
HDL2b was significantly lower for the middle and high
HDL-C subgroups only in the high LDL-C group in
comparison with the corresponding HDL-C subgroup in
the desirable LDL-C group.
Correlation coefficients between plasma lipids, ratios of
lipids, and the apoA-I contents of HDL subclasses
(controlling for TG)
After controlling for TG levels, correlation analysis
results revealed that TC and LDL-C levels were posi-
tively correlated with preb1-HDL and HDL3 (HDL3c,
HDL3b,H D L 3a) but negatively correlated with HDL2a
(TC) and HDL2b. The ratios of TC/HDL-C and LDL-C/
HDL-C were significantly positively correlated with
preb1-HDL but inversely correlated with HDL2a and
HDL2b. Additionally, the HDL-C concentration was
positively related to all HDL subclasses (Table 3).
Relationship of plasma apoA-I contents of HDL subclasses
with levels of lipids, and ratios of lipids by multivariate
stepwise regression analysis
To obtain a more complete understanding of the deter-
minants of HDL subclass distribution, we performed
stepwise multivariate regression analysis with the con-
tents of all HDL subclass as dependent variables and the
levels of TC, LDL-C, and HDL-C along with the ratios
of TC/HDL-C and LDL-C/HDL-C as independent
variables.
Table 4 shows that the contents of preb1-HDL,
HDL3b,H D L 3a as well as HDL2a and HDL2b were
Table 2 The apoA-I contents of plasma HDL subclasses according to values of LDL-C/HDL-C along with TG levels
LDL-C/HDL-C<3.5 LDL-C/HDL-C≥3.5
Total TG<2.26mmol/L TG≥2.26mmol/L Total TG<2.26mmol/L TG≥2.26mmol/L
N 386 249 137 124 50 74
Preb1-HDL(mg/L) 105.3 ± 20.2 80.4 ± 19.2 134.2 ± 25.5
b§ 120.8 ± 24.4
a* 107.9 ± 21.9
c* 127.8 ± 24.4
b*
Preb2-HDL(mg/L) 56.9 ± 10.8 56.6 ± 10.9 57.2 ± 13.4 59.9 ± 11.2 57.1 ± 11.4 465.0 ± 15.8
HDL3c(mg/L) 74.1 ± 19.7 73.4 ± 21.9 74.7 ± 21.0 75.0 ± 20.6 72.2 ± 19.8 76.9 ± 19.5
HDL3b(mg/L) 148.0 ± 25.9 145.2 ± 27.4 151.1 ± 28.6 150.0 ± 26.3 149.8 ± 24.4 163.8 ± 29.0
HDL3a(mg/L) 283.5 ± 34.6 241.5 ± 30.1 297.5 ± 70.8
b† 309.2 ± 32.5
a* 286.9 ± 66.9
c* 336.3 ± 38.9
b§c†
HDL2a(mg/L) 287.2 ± 29.0 320.8 ± 56.4 255.6 ± 31.0
b§ 243.7 ± 29.1
a† 275.1 ± 29.1
c† 210.8 ± 29.2
b*c†
HDL2b(mg/L) 339.3 ± 41.7 374.7 ± 81.5 305.1 ± 35.1
b§ 260.2 ± 28.9
a§ 302.9 ± 78.9
c§ 221.1 ± 21.5
b†c
Values are expressed as Mean ± S.D
*P <0 . 0 5 ,
†P <0 . 0 1 ,
§P < 0.001
aCompared with the Total subgroup within the LDL-C/HDL-C<3.5 group
bCompared with the TG<2.26mmol/L subgroup within the same LDL-C/HDL-C ratio group
cCompared with the LDL-C/HDL-C<3.5 subgroup within the same TG level group
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Page 3 of 10Figure 1 The apoA-I contents of preb1-HDL and HDL2b according to the concentrations of LDL-C and HDL-C. Values are expressed as
means. The values in the < > denote the LDL-C/HDL-C ratio; n: numbers; *P < 0.05, **P < 0.01, ***P < 0.001, compared with the HDL-C < 1.03
mmol/L subgroup within the same LDL-C group.
§P < 0.05,
§§P < 0.01,
§§§P < 0.001, compared with the same HDL-C subgroup within the LDL-C
< 3.34 mmol/L group
Table 3 Correlation coefficients between plasma lipids along with lipids ratios and apoA-I contents of HDL subclasses
















TC .395 .000 .110 .013 .217 .000 .289 .000 .110 .013 -0.117 .008 -.154 .001
LDL-C .382 .000 .059 .184 .159 .000 .240 .000 .095 .032 .015 .743 -.228 .000
HDL-C .150 .001 .131 .003 .164 .000 .141 .001 .099 .030 .187 .000 .270 .000
TC/
HDL-C
.138 .002 -.036 .414 -.013 .768 .017 .699 .026 .555 -.174 .000 -.303 .000
LDL-C/
HDL-C
.178 .000 -.034 .439 .008 .859 .043 .338 .034 .440 -.160 .000 -.301 .000
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Page 4 of 10significantly and independently predicted by the ratios of
TC/HDL-C and LDL-C/HDL-C. Furthermore, TC was a
significant independent negative predictor of the larger
sizes of HDL2a and HDL2b; LDL-C was associated posi-
tively with the smaller sizes of HDL3b and HDL3a,i n
addition to the ratios of TC/HDL-C and LDL-C/HDL-
C. The levels of TC, HDL-C, and LDL-C also made a
significant contribution to preb1-HDL, preb2-HDL and
HDL3c.
Discussion
Increased levels of LDL-C and reduced levels of HDL-C
are considered highly atherogenic. The LDL-C/HDL-C
ratio possessed more prognostic value than LDL-C and
HDL-C alone. In several studies, the LDL-C/HDL-C
ratio has emerged as the best single lipid predictor of
CHD risk [18]. Previous reports from the Monitored
Atherosclerosis Regression Study (MARS) indicated that
the LDL-C/HDL-C ratio was significantly associated
with the progression of both low-grade and high-grade
coronary artery lesions [19]. At the same time, the data
showed that for every 1% reduction in the LDL-C/HDL-
C ratio, there was a 31% reduction in the risk of a
major cardiovascular event (MCVE) [20].
Total HDL in humans consists of several major and
minor particle subclasses, where not all the HDL sub-
class particles have the same antiatherogenic potential.
Minor variations in HDL subclass particle distribution
might potentially cause larger variations in the coronary
risk [21]. Some studies have demonstrated that both the
severity and progression of CAD are related to the
plasma concentration of individual HDL subclasses [22].
Thus, in this work, we mainly clarified the influence of
the LDL-C/HDL-C ratio on HDL subclass distribution
phenotype, which could have important implications.
According to the assessment from the Quebec Cardio-
vascular Study and calculated odds ratios for ischemic
heart disease (IHD), increased IHD risk in the 3.9 to 4.6
and > 4.6 subgroups of the LDL-C/HDL-C ratio (odds
ratio 3.4 and 3.7, respectively) compared with IHD odds
ratio for the ≤ 2.3 along with the 2.3 to 3.9 LDL-C/
HDL-C subgroups were 1.0 and 1.9, respectively [23].
Results from the current study revealed that, when
accompanied by the elevation of the LDL-C/HDL-C
Table 4 Multiple stepwise regression correlation between contents of plasma HDL subclasses and concentrations of
lipids along with ratios of lipids
Unstandardized Coefficients Standardized Coefficients tp
B Std. Error Beta
Preb1-HDL(mg/dL) LDL-C/HDL-C 29.39 2.97 .749 9.89 .000
TC 29.32 2.83 .606 10.36 .000
TC/HDL-C 15.75 1.79 .555 5.63 .000
HDL-C 32.33 3.02 .292 3.58 .000
Preb2-HDL(mg/dL) TC 6.59 0.73 .282 3.67 .000
LDL-C 4.49 0.51 .201 2.61 .009
HDL3c(mg/dL) TC 6.15 0.37 .195 4.48 .000
HDL-C 9.37 0.54 .130 2.98 .003
HDL3b(mg/dL) TC/HDL-C 28.37 2.42 .831 2.72 .007
LDL-C/HDL-C 46.86 4.14 .993 3.31 .001
LDL-C 47.58 2.67 .854 3.24 .001
HDL3a(mg/dL) TC/HDL-C 28.93 3.26 .535 4.62 .000
LDL-C/HDL-C 42.56 4.01 .569 3.87 .000
LDL-C 21.46 2.04 .243 3.05 .002
HDL2a(mg/dL) TC/HDL-C -26.60 3.77 -.566 -7.06 .000
LDL-C/HDL-C -14.36 1.56 -.221 -2.58 .000
TC -13.66 1.19 -.171 -3.60 .010
HDL2b(mg/dL) TC/HDL-C -55.52 5.16 -.801 -10.76 .000
LDL-C/HDL-C -41.08 3.61 -.429 -5.39 .000
TC -12.68 1.15 -.107 -2.44 .015
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Page 5 of 10ratio, the contents of small-sized preb1-HDL, HDL3a,
and HDL3b increased progressively but those of large-
sized HDL2a and HDL2b decreased progressively. In the
LDL-C/HDL-C ≤ 2.3 group, the contents of preb1-HDL
and HDL2b were 81.2 ± 20.2 and 387.3 ± 95.7 mg/dL,
respectively. It is noteworthy that large-sized HDL2a and
HDL2b occupied approximately 52.7% of the contents of
HDL subclasses, the ratio of HDL2b/preb1-HDL was
approximately 4.8 in the LDL-C/HDL-C ≤ 2.3 group,
and the distribution pattern of HDL subclass was con-
sistent with the normolipidemic subjects in our previous
report [15]. Compared with the LDL-C/HDL-C ≤ 2.3
group, an increase (27%, 50%, and 77%) in preb1-HDL
and a decrease (24%, 48%, and 88%) in HDL2b were
found in the 2.3 < LDL-C/HDL-C ≤ 3.9, 3.9 < LDL-C/
HDL-C ≤ 4.6 and LDL-C/HDL-C > 4.6 groups,
respectively.
The description of HDL subclass distribution remodel-
ing above might result from increased LDL-C and TG
and decreased HDL-C levels. Many previous studies
have indicated that enhanced CETP and HL activities
are correlated with various levels of HDL-C[24,25].
CETP exchanges cholesteryl esters (CE) of HDL2 with
TGs of very low density lipoprotein (VLDL) and LDL.
The HDL-derived CE is removed from the circulation
via the LDL receptor pathway. TGs in HDL are hydro-
lyzed by HL. The concerted action of CETP and HL
converts larger HDL2 into smaller HDL3 and releases
lipid-free apoA-I and/or preb1-HDL [26-28]. On the
other hand, a significant increase in TG levels with a
rise in the LDL-C/HDL-C ratio was also observed in
this study. It has been reported that high levels of TG
are associated with impaired LPL and LCAT activities
[29,30]. LPL is principally responsible for the hydrolysis
of TGs in TG-rich lipoprotein (TRL) and the release of
free fatty acids, transforming large TRL particles into
smaller TG-depleted remnant lipoproteins. During this
process, redundant surface lipid (FC and PL) and apos
are transferred from TRL to HDL3, resulting in the for-
mation of HDL2 particles. LCAT plays an important
role in the maturation of nascent to mature HDL cata-
lyzed by the transfer of 2-acyl groups from lecithin to
FC, generating CE and lysolecithin. Hydrophobic CE is
retained in the HDL core, promoting the conversion of
preb1-HDL and HDL3 to HDL2. Thus, it has been sug-
gested that a high LDL-C/HDL-C ratio is associated
with low levels of large-sized HDL2 and generally with
small-sized HDL particles.
Furthermore, several prospective studies [31,32] have
revealed that a high LDL-C/HDL-C ratio combined with
hypertriglyceridemia (HTG) is associated with the high-
est incidence of CHD. Castelli, et al. [33] observed that
the average LDL-C/HDL-C ratio for people without
CHD was below 3.4, while the ratio values for patients
with excessive rates of CHD were at least 3.5. It is com-
monly thought that a desirable ratio of LDL-C/HDL-C
is 3.5, which has been used as an indicator of coronary
atherosclerosis [33]. Thus, in this context, we selected
values of 3.5 for the LDL-C/HDL-C ratio and 2.26
mmol/L for TG, based on ATP-III guidelines, as critical
cut-off points to examine the joint effect of the LDL-C/
HDL-C ratio together with TG levels on the change in
HDL subclass distribution.
The present results show increased contents of small-
sized preb1-HDL and HDL3a and decreased contents of
large-sized HDL2a,a n dH D L 2b in the LDL-C/HDL-C ≥
3.5 group versus the LDL-C/HDL-C < 3.5 group, which
indicated that the metabolism of HDL subclasses in the
LDL-C/HDL-C ≥ 3.5 group was abnormal. In addition,
there are 249 subjects, accounting for almost half of the
total subjects in the TG < 2.26 mmol/L along with the
LDL-C/HDL-C < 3.5 group; furthermore, the distribu-
tion of HDL subclass was also concordant with normoli-
pidemic subjects from our previous study. On the
contrary, the HDL subclass distribution in the TG ≥
2.26 mmol/L together with LDL-C/HDL-C ≥ 3.5 group
was characterized by elevated contents of small-sized
preb1-HDL, while large-sized HDL2 declined. That
resulted in a drastic reduction of HDL2b/preb1-HDL (4.7
down to 1.7) and the percentage of the mature HDL2a
and HDL2b (53.8% down to 35.7%), compared to the TG
< 2.26 mmol/L group along with the LDL-C/HDL-C <
3.5 group. It indicated that HDL metabolic disorders
and HDL maturation are blocked in the TG ≥ 2.26
mmol/L along with the LDL-C/HDL-C ≥ 3.5 group. At
the same time, it is reported that the most common
hyperlipidemia in the Chinese population is character-
ized by elevated TG levels (e.g., HTG), which accounts
for about 61% of total hyperlipidemia [8]. In this regard,
it is important to point out that applying the LDL-C/
HDL-C ratio to estimate the risk of CHD should be
combined with the effect of individual TG levels, parti-
cularly in the Chinese population.
The current NCEP (ATP-III) guidelines recommend
specific target levels of LDL-C and HDL-C for deter-
mining CVD risk and assessing the effectiveness of
lipid-lowering therapies. The interaction of concentra-
tions of LDL-C and HDL-C and values of the LDL-C/
HDL-C ratio with HDL subclass distribution was also
investigated in our study. We observed in subjects with
low HDL-C levels a marked increased in the LDL-C/
HDL-C ratio (3.0, 4.3, and 5.7), and the contents of
HDL2b decreased progressively and significantly, and all
three remained at lower concentrations (284.6, 263.4
and 227.4 mg/L); however, contents of preb1-HDL
stayed at higher concentrations (131.7, 107.6, and 115.3
mg/L) in the desirable LDL-C (< 3.34 mmol/L), border-
line LDL-C (3.36-4.11 mmol/L) and high LDL-C (≥ 4.14
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Page 6 of 10mmol/L) groups, respectively, with elevation of LDL-C
levels. These findings suggest that in low concentrations
of HDL-C, abnormalities in the HDL particle profile
occur regardless of whether the LDL-C levels increased
or not. Moreover, other studies have demonstrated that
low HDL-C increased the risk of CVD, even when LDL-
C was normal or without marked elevation [2,34].
On the other hand, we also noted that in high LDL-C
level (≥ 4.14 mmol/L) subjects who had a relatively low
LDL-C/HDL-C ratio (2.8), the distribution in the HDL
subclass was substantially altered and characterized by
increased small-sized preb1-HDL (169.5 mg/L) and dras-
tically falling large-sized HDL2b (251.1 mg/L), which
resulted in an extreme low value of HDL2b/preb1-HDL
(1.4) in spite of the higher concentrations of HDL-C.
The opposite of this pattern was observed in the border-
line LDL-C (3.36-4.11 mmol/L) and desirable LDL-C (<
3.34 mmol/L) groups, and the subjects in these two
groups had significantly higher HDL2b/preb1-HDL
values (4.4 and 5.4, respectively) and maintained the dis-
tribution of the HDL subclass in a normal or near-nor-
mal profile. Specific HDL subclasses are involved in
certain steps of RCT, and a low HDL2b/preb1-HDL ratio
is a signature pattern of disturbed HDL metabolism and
RCT, implying that higher concentrations of HDL-C do
not correct the abnormal HDL subclass distribution for
subjects with high levels of LDL-C (≥ 4.14 mmol/L).
Furthermore, it is interesting to note that there was a
significant reduction of the HDL2b/preb1-HDL ratio (2.1
and 1.4), although there was a lower ratio of LDL-C/
HDL-C (3.0 and 2.8) according to the Castelli risk
indices (< 3.5) in both the desirable LDL-C-low HDL-C
and high LDL-C-high HDL-C groups. The correlation
analysis results also support the above observations. The
levels of TC and LDL-C together with the ratios of TC/
HDL-C and LDL-C/HDL-C were positively correlated
with preb1-HDL, while there was the inverse relation-
ship with HDL2b; the plasma HDL-C level was positively
related to preb1-HDL and HDL2b in both univariate and
stepwise regression analyses (Tables 3 and 4). These
findings together suggest that the levels of LDL-C and
HDL-C along with the values of LDL-C/HDL-C should
be considered simultaneously while assessing the HDL
subclass metabolism and determining CVD risk.
It is worthwhile to point out that diets high in carbo-
hydrates are prevalent in China, resulting in increased
concentrations of plasma glucose and, thus, high insulin
levels. Hyperinsulinemia stimulates the production and
secretion of TG and VLDL, which lead to relatively
higher TG and lower HDL-C levels. The typical high
TG and low HDL-C in the Chinese population are
accompanied by the abnormal distribution of the HDL
subclass. Based on the abovementioned, the elevated TG
along with reduced HDL-C levels might be the cause of
the alteration of the HDL subclass distribution in the
Chinese population. Unlikeness, Western populations
usually have a high saturated f a td i e t( W e s t e r nt y p eo f
diet), and an increase in dietary fat will elevate plasma
TC and LDL-C concentrations [35-37]. Also, levels of
TC and LDL-C [24,38] showed a positive correlation
with CETP and HL activities, which favor the formation
of small-sized HDL particles. The concentration of
plasma lipids could be an important factor impacting
the HDL subclass distribution in the Western
population.
Conclusions
Overall, the results of this study suggest that a general
shift toward smaller-sized HDL was accompanied by an
increase of the LDL-C/HDL-C ratio, suggesting that the
maturation process of HDL was blocked. The shift men-
tioned above would be more obvious with a high LDL-
C/HDL-C ratio and elevated TG levels. The HDL sub-
class distribution can be effectively normalized by a high
HDL-C concentration at desirable borderline LDL-C
levels (< 4.11 mmol/L). The influence of higher LDL-C
levels on the HDL subclass, however, cannot be coun-
teracted by higher HDL-C levels.
Methods
Subjects
This protocol was approved by West China Hospital,
Sichuan University (Chengdu 610041, China). Five hun-
dred ten subjects (323 men; mean age, 56.2 ± 9.0 years;
187 women; mean age, 56.5 ± 9.2 years) were recruited
to participate in a study examining plasma lipid and apo
concentrations at West China Medical Center, Sichuan
University. Exclusion criteria were the following: (1) the
presence of nephrosis, diabetes mellitus, hypothyroidism,
or hepatic impairment; (2) the presence of a major car-
diovascular event (myocardial infarction, severe or
unstable angina pectoris, and surgery) or stroke; (3) tak-
ing lipid-altering medications; or (4) a history of alcohol
abuse and smoking cigarettes. Informed consent was
obtained from each subject upon entry into the study
population. This study protocol was approved by the
ethics committee.
To study the relationship between the LDL-C/HDL-C
ratio and HDL subclass distribution, we divided these
subjects into four subgroups using the cut-off points of
less than 2.3, 2.3 to 3.9, 3.9 to 4.6, and higher than 4.6,
as suggested by the Quebec Cardiovascular Study [23].
The average LDL-C/HDL-C ratio was 3.5 or higher [33]
and has been suggested as a value indicating increased
CHD risk. We also assessed the joint effect of the LDL-
C/HDL-C and TG levels on the HDL subclass distribu-
tion based on 3.5 for LDL-C/HDL-C and 2.26 mmol/L
for TG as the cut-off points. The alteration of the LDL-
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HDL subclass distribution was also investigated in the
current work. The reference levels of the plasma lipids
were defined by following guidelines from the Adult
Treatment Panel III (ATP-III) of the National Choles-
terol Education Program (NCEP) [39], that is: desirable
LDL-C (< 130 mg/dL; 3.34 mmol/L), borderline LDL-C
(130-160 mg/dL; 3.36-4.11 mmol/L), high LDL-C (≥ 160
mg/dL; 4.14 mmol/L), low HDL-C (< 40 mg/dL; 1.03
mmol/L), middle HDL-C (40-60 mg/dL; 1.03-1.55
mmol/L), and high HDL-C (≥ 60 mg/dL; 1.55 mmol/L).
Specimens
Whole blood specimens were drawn after a 12 h over-
night fast into EDTA-containing tubes. Plasma was
separated within 1-2 h. Plasma was stored at 4°C and
used for lipid and apo analyses within 24 hours. An ali-
quot of plasma was stored at -70°C for the determina-
tion of HDL subclasses.
Plasma lipid and apolipoprotein analyses
Plasma TG, TC and HDL-C concentrations were mea-
sured by the standard technique. TC and TG were
determined with enzymatic kits (Beijing Zhongsheng
Biotechnological Corporation, Beijing, and People’s
Republic of China). The HDL-C was determined after
precipitation of the apoB-containing lipoproteins by
phosphotungstate/magnesium chloride [40]. LDL-C was
calculated using the Friedwald formula (TG < 4.52
mmol/L) [41]. When plasma TG was at least 4.52
mmol/L, LDL-C was determined following the precipita-
tion method with polyvinylsulfate (enzymatic kits).
Plasma apoA-I, B-100, C-II, and C-III were determined
by radial immunodiffusion methods [42] using kits
developed at the Apolipoprotein Research Laboratory,
West China Medical Center, Sichuan University. The
intraassay coefficient of variation for apo concentrations
was between 2.1% and 4.8%; the interassay coefficient of
variation was 3.5% to 7.9% [43].
High density lipoprotein cholesterol subclass analysis
ApoA-I-containing HDL subclasses were measured by
nondenaturing two-dimensional gel electrophoresis asso-
ciated with the immunodetection method, as described
previously [7]. Briefly, 10 μl of plasma was first sepa-
rated by charge on 0.7% agarose gel into preb and a
mobility particles. In the second dimension, the two
fractions of HDL were further separated according to
size by 2-30% nondenaturing polyacrylamide gradient
gel electrophoresis. Western blotting was conducted to
determine HDL subclasses after electrophoresis using
horseradish peroxidase (HRP)-labeled goat anti-human
apoA-I immunoglobulin G (IgG). The HDL particle
sizes were calibrated using a standard curve that
included bovine serum albumin, ferritin and thyroglobu-
lin (Pharmacia, Uppsala, Sweden). The calculation of the
relative percentage of each HDL subclass was based on
the density of the electrophoresis spots. Then, the
apoA-I contents (in milligrams per liter) of the HDL
subclasses were calculated by multiplying the percentage
of each subclass by the plasma total apoA-I concentra-
tions. The interassay coefficients of variation of the rela-
tive concentration of preb1-HDL, preb2-HDL, HDL3c,
HDL3b, HDL3a, HDL2a, and HDL2b in the plasma sample
were 9.4%, 9.8%, 4.9%, 6.2%, 7.3%, 11.1% and 7.9%,
respectively (n = 5).
Statistical analysis
All statistical analyses were performed using the statisti-
cal package SPSS Version 13.0 (SPSS, Chicago, IL). Data
in the tables are expressed as mean ± S.D. The Duncan
post-hoc test was used in situations in which a signifi-
cant group (one-way analysis of variance) effect was
observed. Pearson correlation coefficients were calcu-
lated to quantitatively analyze the associations among
variables adjusted for TG concentration. Multivariate
stepwise regression analyses were computed to estimate
the independent contribution of metabolic variables to
the distribution of HDL subclasses. In all comparisons,
P less than 0.05 (2-sided) represented a statistically sig-
nificant difference.
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